In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstaZeneca shares with a ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

Atrioventricular interval modulation is being studied for patients with uncontrolled hypertension. Could the new technology ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Fewer than 10 percent of people with hypertension had their blood sugar under control & fewer than 66 percent of diabetics ...

NIE reveals that Indians consume excessive salt, increasing the risk of hypertension and related diseases. To combat this, ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...

Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...